Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II–III Breast Cancer
Valentina Guarneri(Istituto Oncologico Veneto), Pietro Torricelli(University of Modena and Reggio Emilia), Claudia Mauri(The Royal Free Hospital), Rachele Battista(University of Modena and Reggio Emilia), PierFranco Conte(University of Padua), Guido Ficarra(University of Modena and Reggio Emilia), Elena Barbieri(Consejo Nacional de Investigaciones Científicas y Técnicas), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Giovanni Tazzioli(Azienda Ospedaliero-Universitaria di Modena), Barbara Canossi(University of Modena and Reggio Emilia), Maria Vittoria Dieci(Istituto Oncologico Veneto), Annarita Pecchi(Azienda Ospedaliero-Universitaria di Modena), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Roberto D’Amico(University of Modena and Reggio Emilia)
Cited by 21
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830